ReviewBiotechnology reports (Amsterdam, Netherlands)2025
Biogenic copper and copper oxide nanoparticles to combat multidrug-resistant
Review in Biotechnology reports (Amsterdam, Netherlands), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
8 citing papers in PubMed.
- Combating multidrug-resistant pathogens, breast cancer (MCF-7) and hepatocellular carcinoma (HepG2) using biofabricated zinc oxide nanoparticles.Scientific reports · 2026Article
- Copper/Copper Oxide Nanoparticles: Biological Synthesis, Characterization and Potential Biomedical Applications: Advances and Perspectives.Pharmaceuticals (Basel, Switzerland) · 2026Review
- Biogenic Metal Nanoparticles from Indian Flora as Programmable Bio-Interfaces: From Phytochemical Coronas to Precision Nanomedicine.International journal of molecular sciences · 2026Review
- Eco-friendly optimization and green biosynthesis of Cu(II) nanocomposites from Stereum ostrea biomass extract: enhanced antibiofilm efficacy against pathogenic bacteria.Discover nano · 2026Article
- Facile one-pot construction of copper-loaded polydopamine films on NiTi alloy for adjustable antibacterial activity and enhanced corrosion resistance.RSC advances · 2026Article
- Multifunctional nanostructured lipid carriers encapsulating Bacillus megaterium supernatant and magnetic nanoparticles for combating methicillin-resistant Staphylococcus aureus and cancer cells.BMC microbiology · 2025Article
- Engineering copper and copper-based materials for a post-antibiotic era.Frontiers in bioengineering and biotechnology · 2025Review
- Antifungal, Antibiofilm and Anticytotoxic Properties of Biogenic CuO Nanoparticles Derived FromInternational journal of women's health · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Antimicrobial resistance has increased alarmingly in recent years, with the World Health Organization identifying multidrug-resistant Objective: This review uniquely evaluates the emerging evidence for biosynthesized copper nanoparticles as a sustainable, cost-effective, and potentially alternative to conventional antibiotics against multidrug-resistant Methods: We systematically analyzed current literature on green synthesis methods for copper and copper oxide nanoparticles, their characterization techniques, antimicrobial mechanisms, and efficacy against multidrug-resistant Results: Unlike other metal nanoparticles, biosynthesized copper nanoparticles demonstrate significant antibacterial activity against multidrug-resistant Conclusion: This broad assessment of biosynthesized copper nanoparticles shows strong potential as a therapy against MDR
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.